Geron Corporation (GERN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Geron Corporation (GERN) has a cash flow conversion efficiency ratio of -0.275x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.91 Million) by net assets ($229.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Geron Corporation liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Geron Corporation - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Geron Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Geron Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Geron Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ponsse Oyj 1
HE:PON1V
|
-0.035x |
|
Suzhou Xianglou New Material Co. Ltd.
SHE:301160
|
-0.019x |
|
Kornit Digital Ltd
NASDAQ:KRNT
|
0.009x |
|
SNT Dynamics Co Ltd
KO:003570
|
-0.026x |
|
Daewon Cable Co. Ltd. Preference Shares
KO:006345
|
-0.036x |
|
Zhejiang Tiancheng Control Co
SHG:603085
|
0.112x |
|
Paul Hartmann AG
F:PHH2
|
0.021x |
|
Fujian SuperTech Advanced Material Co Ltd
SHG:688398
|
0.016x |
Annual Cash Flow Conversion Efficiency for Geron Corporation (1996–2025)
The table below shows the annual cash flow conversion efficiency of Geron Corporation from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see GERN market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $225.87 Million | $-111.04 Million | -0.492x | +36.97% |
| 2024-12-31 | $280.32 Million | $-218.62 Million | -0.780x | -15.28% |
| 2023-12-31 | $247.95 Million | $-167.74 Million | -0.677x | +57.51% |
| 2022-12-31 | $80.00 Million | $-127.38 Million | -1.592x | -110.65% |
| 2021-12-31 | $126.42 Million | $-95.56 Million | -0.756x | -139.23% |
| 2020-12-31 | $210.95 Million | $-66.65 Million | -0.316x | +2.57% |
| 2019-12-31 | $135.16 Million | $-43.83 Million | -0.324x | -174.34% |
| 2018-12-31 | $177.73 Million | $-21.01 Million | -0.118x | +40.31% |
| 2017-12-31 | $103.80 Million | $-20.56 Million | -0.198x | -31.94% |
| 2016-12-31 | $122.38 Million | $-18.37 Million | -0.150x | +11.83% |
| 2015-12-31 | $142.13 Million | $-24.20 Million | -0.170x | -338.00% |
| 2014-12-31 | $130.71 Million | $9.35 Million | 0.072x | +111.65% |
| 2013-12-31 | $59.76 Million | $-36.68 Million | -0.614x | +4.66% |
| 2012-12-31 | $85.65 Million | $-55.15 Million | -0.644x | -51.28% |
| 2011-12-31 | $146.60 Million | $-62.39 Million | -0.426x | -85.19% |
| 2010-12-31 | $192.74 Million | $-44.29 Million | -0.230x | +8.56% |
| 2009-12-31 | $172.58 Million | $-43.37 Million | -0.251x | -0.84% |
| 2008-12-31 | $168.46 Million | $-41.98 Million | -0.249x | -92.48% |
| 2007-12-31 | $205.67 Million | $-26.63 Million | -0.129x | +14.63% |
| 2006-12-31 | $173.92 Million | $-26.38 Million | -0.152x | -40.32% |
| 2005-12-31 | $190.71 Million | $-20.61 Million | -0.108x | +49.11% |
| 2004-12-31 | $122.06 Million | $-25.93 Million | -0.212x | +7.43% |
| 2003-12-31 | $106.32 Million | $-24.40 Million | -0.229x | +78.23% |
| 2002-12-31 | $29.74 Million | $-31.34 Million | -1.054x | -189.24% |
| 2001-12-31 | $61.54 Million | $-22.42 Million | -0.364x | -71.18% |
| 2000-12-31 | $63.92 Million | $-13.61 Million | -0.213x | +58.99% |
| 1999-12-31 | $26.20 Million | $-13.60 Million | -0.519x | -118.28% |
| 1998-12-31 | $32.80 Million | $-7.80 Million | -0.238x | +36.49% |
| 1997-12-31 | $21.10 Million | $-7.90 Million | -0.374x | +10.75% |
| 1996-12-31 | $23.60 Million | $-9.90 Million | -0.419x | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more